← Leaderboards
Brent M Egan
Medical University Of South Carolina
$2,811,640
Attributed
$3,143,515
Total exposure
17
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $331.9K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,143,515 · 16
AHRQ$0 · 1
By mechanism
R01$1,380,851 · 1
R34$663,750 · 1
K24$653,751 · 1
M01$445,163 · 11
P01$0 · 1
P60$0 · 2
Top collaborators
- Marilyn Laken2 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Julie Chao$9,369,252
- Marilyn Laken$331,875
- Donald R. Menick$17,263,987
- Ayad A Jaffa$7,063,873
- Eni C Okonofua$213,959
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHypertensionObesityBlood PressureNutrition Related TagOxidative StressFatty AcidsAntihypertensive AgentsAngiotensinsHuman Therapy EvaluationProtein Kinase CVascular ResistanceVascular Smooth MuscleClinical TrialsDrug Screening /EvaluationHeparinCardiovascular Disorder ChemotherapyDietary SodiumInsulin Sensitivity /ResistanceDietDisease /Disorder Proneness /RiskLow Birth Weight Infant HumanBaroreflex
Grant awards (40)
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study$331,875
R34 · FY2012 · HL
Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study$331,875
R34 · FY2011 · HL · contact PI
PROTEOMIC ANALYSIS OF BLOOD: ZN-ALPHA-2-GLYCOPROTEIN AS A BIOMARKER FOR CACHE$2,325
M01 · FY2008 · RR · contact PI
FATTY ACIDS, ANGIOTENSIN AND OXIDATIVE STRESS$63,191
M01 · FY2007 · RR · contact PI
FATTY ACIDS, ANGIOTENSIN AND OXIDATIVE STRESS$204,604
M01 · FY2005 · RR
Fatty Acids, Angiotensin and Oxidative Stress$479,950
R01 · FY2004 · HL
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$149,217
K24 · FY2004 · HL
Fatty Acids, Angiotensin and Oxidative Stress$122,720
M01 · FY2004 · RR
Fatty Acids, Angiotensin and Oxidative Stress$476,810
R01 · FY2003 · HL
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$118,439
K24 · FY2003 · HL
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$30,778
K24 · FY2003 · HL
Fatty Acids, Angiotensin and Oxidative Stress$350,190
R01 · FY2002 · HL
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$118,439
K24 · FY2002 · HL
Fatty Acids, Angiotensin and Oxidative Stress$73,901
R01 · FY2002 · HL
Reducing racial disparity in CV disease through BP control$0
P01 · FY2002 · HS
Research$0
P60 · FY2002 · MD
Research$0
P60 · FY2002 · MD
ORLISTAT PLUS DIET IN OBESE HYPERTENSIVE PATIENTS$0
M01 · FY2002 · RR
PLASMA NEFAS &OXIDATIVE STRESS IN HUMANS$0
M01 · FY2002 · RR
VALSARTAN IN ESSENTIAL HYPERTENSION$0
M01 · FY2002 · RR
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$118,439
K24 · FY2001 · HL
VALSARTAN IN ESSENTIAL HYPERTENSION$0
M01 · FY2001 · RR
VALSARTAN IN ESSENTIAL HYPERTENSION$0
M01 · FY2001 · RR
PLASMA NEFAS &OXIDATIVE STRESS IN HUMANS$0
M01 · FY2001 · RR
PLASMA NEFAS &OXIDATIVE STRESS IN HUMANS$0
M01 · FY2001 · RR
PLASMA NEFAS &OXIDATIVE STRESS IN HUMANS$0
M01 · FY2001 · RR
ORLISTAT PLUS DIET IN OBESE HYPERTENSIVE PATIENTS$0
M01 · FY2001 · RR
ORLISTAT PLUS DIET IN OBESE HYPERTENSIVE PATIENTS$0
M01 · FY2001 · RR
ORLISTAT PLUS DIET IN OBESE HYPERTENSIVE PATIENTS$0
M01 · FY2001 · RR
Reducing racial disparity in CV disease through BP control$0
P01 · FY2001 · HS
VALSARTAN IN ESSENTIAL HYPERTENSION$0
M01 · FY2001 · RR
INSULIN RESISTANCE AND CARDIOVASCULAR RISK FACTORS$118,439
K24 · FY2000 · HL
OBESITY, HYPERTENSION, FATTY ACIDS, AND VASCULAR CONTROL$17,441
M01 · FY2000 · RR
PLASMA NEFAS &OXIDATIVE STRESS IN HUMANS$17,441
M01 · FY2000 · RR
EFFICACY AND SAFETY OF MIBEFRADIL W/ VERAPAMIL IN MILD TO MODERATE HYPERTENSION$17,441
M01 · FY2000 · RR
(SR) MOXONIDINE IN STAGE 1 &2 HYPERTENSION$0
M01 · FY2000 · RR
VALSARTAN IN ESSENTIAL HYPERTENSION$0
M01 · FY2000 · RR
EFFECT OF INTRALIPID &INDOMETHACIN ON PROSTAGLANDIN$0
M01 · FY2000 · RR
ORLISTAT PLUS DIET IN OBESE HYPERTENSIVE PATIENTS$0
M01 · FY2000 · RR
Reducing racial disparity in CV disease through BP control$0
P01 · FY2000 · HS